

Endocrine Management of Gender Incongruence in Adults

Prescribing Guidance for Non-specialist Practitioners

November 2019

(Updated in October 2024 – See ‘Updates’ section for details)

This document has been prepared by Dr Sophie Quinney, Consultant Gender Clinician, and Dr Kate Nambiar, Endocrine Specialist Consultant, with support from the All Wales Prescribing Advisory Group (AWPAG) and the All Wales Therapeutics and Toxicology Centre (AWTTC), and has subsequently been endorsed by the All Wales Medicines Strategy Group (AWMSG).

Please direct any queries to AWTTC:

All Wales Therapeutics and Toxicology Centre
The Routledge Academic Centre
University Hospital Llandough
Penlan Road
Llandough
Vale of Glamorgan
CF64 2XX

awttc@wales.nhs.uk

029 218 26900

The information in this document is intended to help healthcare providers make an informed decision. This document should not be used as a substitute for professional medical advice and although care has been taken to ensure the information is accurate and complete at the time of publication, the All Wales Therapeutics and Toxicology Centre (AWTTC) and All Wales Medicines Strategy Group (AWMSG) do not make any guarantees to that effect. The information in this document is subject to review and may be updated or withdrawn at any time. AWTTC and AWMSG accept no liability in association with the use of its content. Information presented in this document can be reproduced using the following citation:

All Wales Medicines Strategy Group. Endocrine Management of Gender Incongruence in Adults: Prescribing Guidance for Non-specialist Practitioners. November 2019 (Updated October 2024).

Copyright AWTTC 2024. All rights reserved.



Grŵp Strategaeth Meddyginiaethau Cymru Gyfan
All Wales Medicines Strategy Group



Contents

Glossary	2
1.0 Introduction.....	3
2.0 Referral pathway to the Welsh Gender Service for patients aged 17 years and over.	4
3.0 Testosterone therapy – prescribing recommendations	5
3.1 Summary recommendations	5
3.2 Testosterone transdermal gel.....	6
3.3 Short-acting injectable testosterone	7
3.4 Moving to a long-acting injectable testosterone	7
3.5 Long-term monitoring	7
4.0 Estrogen therapy – prescribing recommendations	11
4.1 Summary recommendations:	11
4.2 Estradiol gel.....	12
4.3 Estradiol patches.....	13
4.4 Oral estradiol	13
4.5 Switching from oral estradiol to transdermal therapy.....	13
4.6 Long-term monitoring	14
5.0 Gonadotrophin-releasing hormone agonist and anti-androgen treatments – prescribing recommendations.....	17
5.1 Gonadotrophin-releasing hormone agonists	17
5.2 5-Alpha reductase inhibitors (Finasteride and Dutasteride).....	18
6.0 Self-medication and private care	19
7.0 Menstrual suppression.....	19
7.1 Continuous combined hormonal contraception	19
7.2 Systemic progesterone-based hormonal contraception methods.....	20
7.2.1 Oral medroxyprogesterone acetate (MPA) - Provera.....	20
7.2.2 Injectable Medroxyprogesterone acetate (MPA) - Depo Provera or Sayana Press.....	20
7.3 Intrauterine systems	20
7.4 Gonadotrophin-releasing hormone agonist	20
8.0 Other hormone therapy agents.....	20
9.0 Long-term health screening	21
10.0 Welsh Gender Service contact information.....	21
References	22
Updates	26
Appendix 1. Harm reduction prescribing.....	28
Appendix 2. Short-acting intramuscular testosterone	30

Glossary

BMI	Body mass index
CAMHS	Child and adolescent mental health services
Cisgender	A person whose gender identity corresponds with the sex assigned at birth.
DHT	Dihydrotestosterone
FBC	Full blood count
FSH	Follicle-stimulating hormone
GAHT	Gender affirming hormone therapy
GnRH	Gonadotrophin-releasing hormone agonists
Gender dysphoria	The discomfort or distress that some trans people experience because of the mismatch between their gender identity and sex assignment at birth.
Gender identity	A person's individual understanding of whether they are a man, woman, or something else.
Gender incongruence	The diagnostic term 'transsexualism' has been replaced with 'gender incongruence' ¹ . (This refers to a marked and persistent incongruence between an individual's experienced gender and assignment at birth).
HbA _{1c}	Glycated haemoglobin
LFT	Liver function test
LGT	Local gender team
LH	Luteinizing hormone
Non-binary	A non-binary person has a gender identity that is neither (exclusively) male nor female.
NRT	Nicotine replacement therapy
Off Label	Use of medicines outside their licensed indications
SHBG	Sex hormone binding globulin
SLS	Selected list scheme
Transgender	A person whose gender identity does not correspond with the sex assigned at birth.
Trans men	Individuals assigned female at birth who have a male gender.
Trans women	Individuals assigned male at birth who have a female gender.
WCCG	Welsh Clinical Communications Gateway
WGS	Welsh Gender Service
WGT	Welsh Gender Team
U&E	Urea and electrolytes

1.0 Introduction

This document is intended for practitioners engaged in the prescribing and monitoring of medical therapies used in the management of gender incongruence in adults (over 18 years old). Guidance for people under 18 years old is typically provided by paediatric endocrinology services.

A treatment recommendation is currently made by a gender identity specialist* in the context of a diagnosis of gender incongruence (ICD-11 HA 60.0) and/or gender dysphoria (DSM-5 302.85)¹. This document is also of utility for the purpose of harm reduction prescribing guided by a gender identity specialist (see [Appendix 1](#)).

In making a treatment recommendation, a suitably qualified clinician would be expected to have counselled the patient about the physical and psychological changes that can be anticipated, the risks and limitations of treatment, and the potential impact on their reproductive options. Gamete preservation, if desired, will ideally have been completed, and the patient offered appropriate sexual health and contraceptive advice.


This document recommends some medicines for indications for which they do not have a UK marketing authorisation at the time of publication. For more information on the use of medicines outside their licensed indications ('off-label use'), see the General Medical Council's '[Good practice in prescribing and managing medicines and devices](#)'. Also see AWMSG-endorsed resource '[Understanding unlicensed medicines](#)'.

In Wales, each local health board hosts a Local Gender Team (LGT) comprised of medical practitioners and speech therapists. LGT medical practitioners are responsible for coordinating the initiation and optimisation of hormone therapies at a primary care level, guided by the [Welsh Gender Team](#) (WGT).

An enhanced service supports the prescribing and monitoring of endocrine treatments by GP surgeries². The WGT offer advice via a dedicated clinical enquiries email (contact details under [Section 10.0](#)).

* This would be an individual with evidence of relevant training and at least **two years'** experience working in a specialised gender identity service.

2.0 Referral pathway to the Welsh Gender Service for patients aged 17 years and over.



*Guidance for people under 18 years old is typically provided by paediatric endocrinology services.

3.0 Testosterone therapy – prescribing recommendations

Testosterone gender affirming hormone therapy (GAHT) is used in trans men and non-binary or gender diverse people assigned female at birth seeking physical virilisation changes. For patients requiring full virilisation changes, the aim is to achieve a serum testosterone level equivalent to the mid-range for a cisgender male 15–20 nmol/L ³.

Physical changes are sequential and can take up to 5 years to complete. Some patients use a low dose testosterone therapy regimen under specialist guidance in which case changes can take longer and may be more limited.

Menstrual suppression/cessation of menstruation is typically achieved after 1–6 months of standard dose therapy^{3,4} but for some patients, including those on a low dose regimen, additional treatments may be needed. Treatments used for menstrual suppression in this group are discussed in [Section 7.0](#).

3.1 Summary recommendations:

1. Medical history and physical health including BMI, blood pressure and baseline blood investigations should be reviewed and clinical arising issues should be addressed prior to starting hormone therapy. Clinically significant abnormalities of the baseline test results should be reported to the WGT.

Baseline blood investigations prior to starting testosterone therapy: FBC, U&E, LFT, HbA_{1c}^{*}, fasting lipids, bone profile, prolactin, LH, FSH, serum testosterone, serum estradiol, SHBG, and vitamin D.

2. Smoking cessation should be discussed and strongly encouraged prior to starting testosterone therapy, since smoking further compounds the risk of polycythaemia and cardiovascular disease. Nicotine replacement therapy (NRT) is considered a safe alternative in this scenario. It is good practice to document smoking status at each clinical review. If a patient reports that they have resumed smoking, encourage cessation, offer NRT and contact the WGT for further guidance.
3. Testosterone is neither a contraceptive nor does it prevent sexually transmitted infections. Appropriate sexual and reproductive health advice should be provided when a treatment recommendation is made and at follow up review appointments where relevant⁴.
4. Fertility preservation (gamete cryopreservation) and future fertility options should be discussed prior to initiation of gender affirming hormone therapy.
5. Testosterone therapy should ideally be started using transdermal gel. This offers a more stable testosterone level and has a short half-life so can be easily withdrawn should the need arise. Provided the first or subsequent titration test results are satisfactory, and the patient wishes to do so, they can move from gel treatment to the long-acting intramuscular testosterone undecanoate (Nebido®)⁵. Short-acting intramuscular testosterone is less commonly used in this setting (see [Appendix 2](#)).

Titration blood tests for transdermal gel: FBC and serum testosterone.

* Except in the case of a known haemoglobinopathy; request fasting glucose.

6. Testosterone therapy will cause a fall in HDL-cholesterol and an increase in triglycerides so can lead to an adverse lipid profile⁶. Lipid lowering therapy and/or specialist referral may be needed if significant hyperlipidemia is evident at baseline, particularly if there are other risk factors for cardiovascular disease. There is no need to routinely monitor liver function tests unless they were abnormal at baseline or there is a history of significant liver disease^{7,8}.
7. **Annual testosterone therapy blood tests:** serum testosterone, FBC, LFT, and fasting lipids.

3.2 Testosterone transdermal gel

Testogel® 16.2 mg/g gel⁹ – 20.25 mg testosterone per pump actuation is the most commonly used testosterone gel on the market:

- Starting dose: 2 pumps daily (40.5 mg testosterone)
- Maximum dose: 4 pumps daily (81 mg testosterone)
- It is also available as Testogel® transdermal gel in 40.5 mg¹⁰ and 50 mg¹¹ testosterone sachets.

Testavan® 20 mg/g transdermal gel¹² – 23 mg testosterone per pump actuation can be used as an alternative when Testogel® is unavailable. However, this would be off-label use¹³ since the starting dose recommended is 2 pumps daily (46 mg) not 1 pump daily as recommended in the SPC.

Tostran® 2% gel¹⁴ – 10 mg testosterone per pump actuation

Since the testosterone concentration is lower in Tostran®, it is generally not used for standard dose regimens except where other options are unavailable. Tostran® can also be useful where a lower dose regimen is required. This would however also be an off-label use¹³ of this product.

All gels should be applied each morning to the skin of the inner thigh or abdomen (note - this differs from the recommendations for application sites stated in summary of product characteristics [SPC]) to avoid contamination during blood sampling. Patients should wash their hands thoroughly with soap after application and ensure the area is covered by clothes once the gel dries to avoid skin to skin transfer.

All blood tests, when indicated, should be performed 4–6 hours after the gel is applied. Care should be taken that no gel residue is present at the venepuncture site as this can contaminate the sample and cause a falsely elevated testosterone result.

During the titration phase, blood tests are typically performed every 10 weeks, with review each time (see [Flowchart 1](#)). It is advisable to repeat the test if an unexpectedly high or low testosterone result is observed and to check patient compliance with timing and administration before making a dose adjustment.

Increase the dose by 1 pump at each review until target range is reached. For patients on a standard dose regimen, if the target range of 15–20 nmol/l is not achieved at the maximal dose of gel, consider a switch to injectable testosterone, or seek specialist advice^{9,14}.

3.3 Short-acting injectable testosterone

Short-acting injectable testosterone is generally only recommended where gel therapy is not advised, e.g. in severe skin sensitivity, in circumstances where there is a significant risk of skin-to-skin transfer. This is partly due to the higher rates of polycythaemia observed¹⁵. See [Appendix 2](#) for further information.

3.4 Moving to a long-acting injectable testosterone

Testosterone undecanoate (Nebido®) 1000 mg/4 ml solution for injection⁵ is the most commonly used product on the market and must be administered in a healthcare setting. It is not associated with such wide variation in serum testosterone levels, has lower rates of polycythaemia than other injectable preparations, and only needs to be given approximately every 3 months. This makes it the long-term treatment of choice for most patients seeking full virilisation.

It is common practice for patients to spend time getting accustomed to a short-acting agent (usually transdermal gel) first to ensure they have not encountered unwanted side effects or titration blood abnormalities. If gel treatment is well tolerated, the patient may consider switching to the long-acting testosterone injection (Nebido®). To progress a patient from short-acting treatment to Nebido®, the loading schedule provided in [Flowchart 2](#) is recommended.

In the loading schedule, only the dosing interval is adjusted. The dose (1000 mg/4 ml) remains fixed.

All blood tests, when indicated, should be performed on the day of, or up to 2 days before administration of the injection in order to capture a trough serum testosterone reading.

The frequency of Nebido® injections is set according to the trough serum testosterone reading taken before the final (fourth) loading injection. If it falls inside the target range of 15–20 nmol/L, the injection frequency will be 12-weekly. If it falls outside the target range, adjust the injection frequency by one week in either direction from the standard 12-week interval.

If an interval adjustment is required, blood tests (FBC, LFT, fasting lipids and serum testosterone)^{7,8} * are re-checked on the day of, or up to two days before, the **third** scheduled injection at this new interval to allow time for settling. **Report a trough serum testosterone level greater than 25 nmol/L to the Welsh Gender Team and instigate the reset plan (see [Flowchart 2](#)).**

3.5 Long-term monitoring

Regardless of which type of treatment is used, a patient's testosterone therapy can be considered optimised when two consecutive serum testosterone levels are in target range approximately 6 months apart. At this stage, annual blood monitoring is sufficient.


Treatment with testosterone is usually continued life-long unless medical contraindications arise. The decision to discontinue therapy should be made in collaboration with the patient and the WGT.

* LFT and fasting lipids should be included. This is because by the time the third injection occurs this will be close to 12 months (when the annual bloods are recommended).


Table 1. Testosterone therapy – summary of precautions

Contraindications		Cautions
Breast cancer Pregnancy Breast feeding Primary liver tumour Hypercalcaemia Acute or recent arterial disease		Epilepsy Migraine Hypertension Predisposition to oedema Liver disease Renal insufficiency Obstructive sleep apnoea Ischaemic heart disease
Drug interactions For a comprehensive list consult the British National Formulary (BNF) or the SPC 5,9,12,14		
Warfarin – testosterone may enhance anticoagulant effect.		
Adverse drug reactions For a comprehensive list (including rare and very rare adverse effects), or if significance of possible adverse event is uncertain, consult the Summary of Product Characteristics or BNF.		
The side effect profile and safety of testosterone in trans men is identical to that seen in cisgender males undergoing testosterone replacement for hypogonadism. If you suspect an adverse reaction has occurred, report this to the specialist team. Any serious adverse reactions should also be reported to the MHRA through the “Yellow Card” scheme .		
Clinical condition	Management	
Local irritation	Rotate application/injection sites.	
Mood fluctuations	Particularly with the short-acting injectable formulation given the more pronounced peaks and troughs.	
Polycythaemia	Testosterone therapy stimulates erythropoietin production ¹⁵ Seek advice from Welsh Gender Team if the haematocrit value is greater than 52%. Suspend treatment and seek urgent advice from a haematologist if the value is greater than 60%.	
Obstructive sleep apnoea	Testosterone therapy may exacerbate the symptoms of obstructive sleep apnea. Refer to a specialist in sleep disorders if the patient's condition deteriorates.	
Abnormal lipid profile	Testosterone replacement in trans-men is associated with an increase in triglycerides and a decrease in plasma high density lipoprotein (HDL) cholesterol levels. However, these changes do not appear to alter cardiovascular mortality ¹⁶ . Normal cardiovascular risk assessment applies.	
Future fertility	Patients are informed that treatment with testosterone may temporarily or permanently impair fertility and counselled about their future reproductive options.	
Liver dysfunction	LFT abnormalities are usually minor and do not require treatment to be stopped ^{7,8} . An increase in liver enzymes to more than three times the upper limit of normal requires suspension of treatment; contact the Welsh Gender Team.	

Flowchart 1. Titration: Initiation of transdermal testosterone to standard target 15–20 nmol/L



Flowchart 2. Initiation/loading of long-acting intramuscular testosterone (Nebido®)



4.0 Estrogen therapy – prescribing recommendations

Estrogen gender affirming hormone therapy (GAHT) is used in trans women and non-binary or gender diverse people assigned male at birth seeking physical feminisation changes. The aim of treatment for most patients is to establish a serum estradiol level equivalent to the mid-follicular range 350–750 pmol/L³.

Physical changes are sequential and can take up to 3 years to complete. Some patients may use a low dose regimen under specialist guidance in which case physical changes will take longer and may be more limited¹⁷. For patients seeking full feminisation, titrating towards the upper limit of this range for the first 2–3 years of treatment tends to ensure optimal breast growth, guided by patient-reported breast shape ([Tanner stages](#)¹⁸) and tissue sensitivity.

Venous thromboembolism (VTE) is the most significant risk associated with estrogen therapy especially in older people and those on estrogen therapy for long durations¹⁹. In the population overall, age, smoking and high BMI have been consistently associated with a higher VTE risk²⁰.

Transdermal estrogen has been shown to have a lower risk of VTE in cisgender post-menopausal women using it for hormone replacement compared to oral estradiol²¹. Hence transdermal estrogen is recommended as first line, although patient choice is an important factor to consider.

Synthetic estrogens (e.g. ethinylestradiol) or conjugated equine estrogens should not be prescribed as there is an unacceptably high risk of venous thromboembolism. Patients using these treatments should be advised to switch to one of the formulations recommended in this guidance document³.

Although endogenous testosterone release is suppressed, estrogen therapy alone is not usually sufficient to do so fully if the patient requires it. The use of GnRH agonists and other anti-androgen treatment are covered in [Section 5.0](#).

4.1 Summary recommendations:

1. Medical history and physical health including BMI, blood pressure and baseline blood investigations should be reviewed and clinical issues arising addressed prior to starting hormone therapy. Clinically significant abnormalities of the baseline test results should be reported to the WGT.

Baseline blood investigations before starting treatment: FBC, U&E, LFT, HbA_{1c}^{*}, fasting lipids, bone profile, prolactin, LH, FSH, testosterone, estradiol, SHBG, and vitamin D. Add prostate-specific antigen (PSA) in patients aged 50 years and older²².

2. Smoking cessation should be discussed and strongly encouraged prior to starting estrogen therapy, as the risk of venous thromboembolism and cardiovascular disease is increased²³. Nicotine replacement therapy (NRT) is considered a safe alternative in this scenario. It is good practice to document smoking status at each clinical review. If a patient reports that they have resumed smoking, encourage cessation, offer NRT and contact the WGT for further guidance.

* Except in the case of a known haemoglobinopathy; request fasting glucose.

3. Estradiol is neither a contraceptive nor does it prevent sexually transmitted infections. Appropriate sexual and reproductive health advice should be provided when a treatment recommendation is made and at follow up review appointments where relevant⁴.
4. Fertility preservation (gamete cryopreservation) and future fertility options should be discussed prior to initiation of gender affirming hormone therapy²⁴.
5. Estrogen therapy should be started using transdermal gel or patches and should be guided by patient preference. Oral estradiol can be offered as an alternative except in patients who are over 40 years old, BMI over 35, smokers, or where there is an otherwise higher risk of venous thromboembolism, cardiovascular disease, or a history of pre-existing liver disease²⁵.
6. **Titration blood tests for estrogen therapy:** serum estradiol, serum testosterone and prolactin.

For all types of estrogen, titration blood tests are performed every 10 weeks, with review each time (see [Flowchart 3](#)). It is advisable to repeat the test if an unexpectedly high or low estradiol result is observed and check patient compliance with timing and administration before making a dose adjustment. There is no need to routinely monitor liver function tests unless they were abnormal at baseline or there is a history of significant liver disease^{7,8}.

8. **Annual blood tests for estrogen therapy:** serum estradiol, serum testosterone, LFT and prolactin.

4.2 Estradiol gel

Estradiol hemihydrate (Sandrena®)²⁶ – 1 mg estradiol per sachet

- Starting dose: 1 sachet daily
- Maximum dose: 5 sachets daily

Estradiol 0.06% (Oestrogel®)²⁷ – 0.75 mg estradiol per pump

- Starting dose: 2 pumps daily (1.5 mg estradiol)
- Maximum dose: 6 pumps daily (4.5 mg estradiol)

Estradiol gel should be applied each morning to the skin of the inner thigh or abdomen (note - this differs from the SPC recommendations for application sites to avoid contamination when blood sampling). Patients should wash their hands thoroughly with soap after application and ensure the area is covered by clothes once the gel dries to avoid skin to skin transfer.

All blood tests, when indicated, should be performed 4–6 hours after the gel is applied. Care should be taken that no gel residue is present at the venepuncture site as this can contaminate the sample and cause a falsely elevated estradiol result.

Increase the dose by 1 sachet or 1 pump at each review until target serum estradiol range is reached. If target range of 350–750 pmol/L is not achieved at the maximum dose of gel, consider a switch to estradiol patches, or seek specialist advice.

4.3 Estradiol patches

Estradot^{®28} or Evorel^{®29} *

- Starting dose: 50 micrograms/24 hours twice weekly
- Maximum dose: 200 micrograms/24 hours twice weekly

Patches can be applied anywhere below the waist. It is worth noting that some brands are affected by exposure to sunlight, and application to the waistline may also risk patches being rubbed off by clothing.

All blood tests, when indicated, should be performed 48 hours after a new patch is applied.

Increase the dose by 50 micrograms/24 hours twice weekly at each review until target serum estradiol range is reached. If target range 350–750 pmol/L is not achieved at the maximum dose of patches, consider a switch to estradiol gel, or seek specialist advice.

4.4 Oral estradiol

Estradiol valerate (Progynova[®])³⁰

Estradiol hemihydrate (Elleste Solo^{®31}, Zumenon^{®32})

- Starting dose: 2 mg daily
- Maximum dose: 8 mg daily

Patients are advised to take the full daily dose in the morning, swallowed whole.

All blood tests, when indicated, should be performed 4–6 hours after tablet(s) are taken.

Increase the dose by 2 mg at each review until target serum estradiol range is reached. If target range 350–750 pmol/L is not achieved at the maximum dose, consider a switch to a transdermal agent or seek specialist advice.

4.5 Switching from oral estradiol to transdermal therapy

When switching from oral to transdermal treatment, patients should be moved to the equivalent dose as per the table below:

Table 2. Dose equivalence when switching from oral to transdermal estradiol

Oral Dose	Transdermal Gel*	Transdermal Patches
2 mg	1 mg	50 mcg
4 mg	2 mg	100 mcg
6 mg	3 mg	150 mcg
8 mg	4 mg	200 mcg

* For **Oestrogel[®]** the closest equivalent dose should be used

Perform a titration blood test at 10 weeks, reviewing the result to see if further dose titration is needed.

* Anecdotal data suggests some brands are preferred for their small size and adhesive quality.

4.6 Long-term monitoring

Regardless of which type of treatment is used, a patient's estrogen therapy can be considered optimised when two consecutive serum estradiol tests are in range approximately 6 months apart. At this stage, annual blood monitoring is sufficient.


Treatment with estrogen is usually continued life-long unless medical contraindications arise. Older patients using oral estradiol are advised to switch to a transdermal formulation due to the increased risk with age of thromboembolism and cardiovascular disease³³. Patients who underwent orchiectomy wanting to reduce their estradiol dose require a serum estradiol level of at least 200 pmol/L to maintain bone density^{34, 35}. The decision to discontinue therapy should be made in collaboration with the patient and the WGT.

Table 3. Estradiol therapy – summary of precautions

Contraindications		Cautions
Breast cancer Thromboembolism <ul style="list-style-type: none">• active• recurrent Thrombophilic disorders Dubin-Johnston and Rotor syndromes Acute liver disease Acute or recent arterial disease Acute porphyria		Obesity Hypertension Ischaemic heart disease Single DVT Family history of thromboembolism and breast cancer Migraine with focal neurology SLE Sickle cell disease Gallstones and liver disorders
Drug interactions		
For a comprehensive list consult the BNF or SPC ²⁶⁻³² .		
There are no drug interactions with transdermal estradiol. The metabolism of oral estradiol can be affected by drugs which act on liver enzymes, such as cytochrome P450. Both enzyme inducers and inhibitors have been shown to have enzyme-inducing properties when used concomitantly with steroid hormones.		
Adverse drug reactions		
For a comprehensive list (including rare and very rare adverse effects), or if the significance of a possible adverse event is uncertain, consult the SPC or BNF.		
Although higher doses are used, estrogen is usually very well tolerated. If you suspect an adverse reaction has occurred this should be reported to the specialist team. Any serious reaction should also be reported to the MHRA through the “Yellow Card” scheme .		
Clinical condition	Management	
Thromboembolic disease	DVT risk is dramatically reduced with newer estrogen formulations ^{3,19} . Advise patients to report symptoms urgently.	
Breast cancer	Risk of breast cancer secondary to estrogen therapy in this patient group* is thought to be lower than for cisgender women ³⁶ . However, uptake of the National Breast Screening program is strongly advised.	
Prostate cancer	Incidence is likely reduced secondary to estrogen therapy ³⁷ , but symptoms should be investigated.	
Fertility impairment	Estrogen therapy can lead to a reduction in spermatogenesis. Patients are counselled that treatment might affect their fertility and are offered sperm storage before starting treatment ²⁴ .	
Liver dysfunction	LFT abnormalities are usually minor and do not require stopping treatment ^{7,8} . An increase in liver enzymes to more than three times the upper limit of normal should prompt advice to be sought from the WGT.	
Hyperprolactinaemia	Serum prolactin may rise with the introduction of estradiol therapy ³⁸ . If there is a new rise of greater than 750 mIU/L, repeat the test. If there is a new rise of greater than 1,000 mIU/L, repeat the test and inform the WGT.	

* Trans women and non-binary or gender diverse people assigned male at birth.

Flowchart 3. Initiation of estrogen to standard target 350–750 pmol/L and introduction of anti-androgen therapies or GnHR agonist therapies



5.0 Gonadotrophin-releasing hormone agonist and anti-androgen treatments – prescribing recommendations

These treatments are particularly helpful for trans women or non-binary/gender diverse patients assigned male at birth who require further androgen suppression when estrogen treatment alone is not sufficient. Some patients use anti-androgen monotherapy under specialist guidance, while others have no requirements and opt for estrogen monotherapy.

5.1 Gonadotrophin-releasing hormone agonists

GnRH agonist medications bind to the GnRH receptor on the pituitary gland, initially stimulating, then downregulating the release of gonadotrophins (luteinizing hormone, follicle-stimulating hormone). With the hypothalamic-pituitary-gonadal (HPG) axis switched off, sex hormone production from the gonads falls significantly.

Patients intending to undergo feminising genital surgery involving orchiectomy are required to achieve prior suppression of testosterone less than 3.0 nmol/L³⁹. For some this can only reliably be achieved through GnRH agonist administration. Post-operatively, this treatment can be stopped.

To avoid triggering menopausal symptoms, GnRH agonist treatment is introduced once the serum estradiol level is greater than 250 pmol/L (see [Flowchart 3](#)).

The first GnRH agonist injection will trigger an initial testosterone flare as GnRH receptors (and production of LH and FSH) are stimulated. Symptoms of this flare are counteracted by the co-administration of cyproterone acetate 100 mg taken once-daily for 14 days. Thereafter, gonadal testosterone production is switched off and remains so for the duration of treatment.

Recommended GnRH agonists:

- **Leuprorelin (Prostap 3 DCS®)**⁴⁰ 11.25 mg intramuscularly every 12 weeks.
- **Triptorelin (Decapeptyl SR®)**⁴¹ 11.25 mg intramuscularly every 12 weeks.

Alternative GnRH agonist:

- **Goserelin (Zoladex LA®)**⁴² 10.8 mg subcutaneously every 12 weeks.

Please note – When prescribing GnRH agonists, the prescriber must endorse the prescription with the reference ‘SLS’.

Available as monthly preparations (Leuprorelin and Triptorelin 3.75 mg every 4 weeks) or (Goserelin 3.6 mg every 4 weeks), if indicated or preferred.

Triptorelin is also available as a 6-monthly preparation (22.5 mg every 24 weeks).

Once testosterone suppression has been confirmed, or after feminising genital surgery involving orchiectomy is completed, routine monitoring of serum testosterone is not necessary as it will reliably be less than 3.0 nmol/L.

With guidance from the WGT, GnRH agonist treatment can be offered to trans men or non-binary/gender diverse patients assigned female at birth if progestin and/or testosterone treatment fails to abolish menstruation/cyclical symptoms (see [Section 7.0 Menstrual suppression](#)).

Table 4. GnRH agonist therapy – summary of precautions

Contraindications
Hypersensitivity to GnRH agonists, its analogues or any other component of the medicinal product
Drug interactions
For a comprehensive list consult the BNF or the Summary of Product Characteristics ⁴⁰⁻⁴²
Androgen suppression can prolong QT interval therefore concomitant use of medication known to prolong the QT interval should be used with care. An ECG should be undertaken to assess baseline QT interval.
Adverse drug reactions
For a comprehensive list (including rare and very rare adverse effects), or if significance of possible adverse event uncertain, consult the Summary of Product Characteristics or BNF.
<p>This treatment is well tolerated and generally not associated with significant side effects.</p> <p>The use of GnRH agonists in conjunction with cross-sex hormone therapy mitigates menopausal symptoms, cardiovascular risk and bone demineralisation.</p> <p>Some patients report short-lived musculoskeletal aching immediately after each injection which resolves after one or two days. Low energy, drive, or sexual desire should be reported to the Welsh Gender Team.</p> <p>If you suspect an adverse reaction has occurred this should be reported to the registered GP. Any serious reaction should also be reported to the MHRA through the "Yellow Card" scheme.</p>

5.2 5-Alpha reductase inhibitors (Finasteride and Dutasteride)

Finasteride⁴³ and Dutasteride⁴⁴ are oral alternatives to a GnRH agonist for use in trans women or non-binary/gender diverse patients assigned male at birth who do not require their testosterone to be fully suppressed. They also help to minimise scalp hair loss, offering long-term protection for those at risk. Treatment can start at the same time as the commencement of estrogen therapy (see [Flowchart 3](#)).

These medicines inhibit 5-alpha reductase, preventing conversion of testosterone into the more potent dihydrotestosterone (DHT).

The serum testosterone level can increase on treatment, but patients should be counselled that this does not mean it is ineffective, as DHT levels will fall. There is no justification for monitoring DHT as the test is not routinely available.

Treatment can be continued with concomitant GnRH agonist administration or after orchiectomy at a reduced dose of ¼ x 5 mg daily for patients wanting to protect against scalp hair loss as a small amount of testosterone is secreted by the adrenal glands.

5-alpha reductase Inhibitor treatment can be used by trans men or non-binary / gender diverse patients assigned female at birth as part of a bespoke regimen under direction from the WGT.

6.0 Self-medication and private care

A significant proportion of patients waiting for NHS gender services are known to self-medicate with treatments purchased from online pharmacies outside the UK, shared with friends or obtained on the 'grey market'⁴⁵.

The WGT offer specialist review and advice around this area. This includes evaluation of a self-medicating patient in support of a general practitioner seeking to meet GMC criteria for harm reduction prescribing (See [Appendix 1](#)).

Some patients will also seek private specialist care. General practitioners may not wish to take responsibility for a patient who is seen by a private specialist. If this is the case then care should remain with the specialist. WGT advice can be requested, if needed, via the dedicated WGS clinical advice email (Contact details under [Section 10.0](#)).

7.0 Menstrual suppression

Menstrual suppression (amenorrhoea) is typically achieved for patients starting testosterone at standard doses within 1–6 months⁴. However, some patients may wish to start a low dose regimen or may not want to have any testosterone at all but still would like menstrual suppression as part of their treatment for gender incongruence.

Moreover, a minority of patients on therapeutic testosterone may still experience menstrual bleeding/cyclical symptoms despite appropriate therapeutic levels. The WGT offers advice to GPs on menstrual suppression for patients via the dedicated clinical advice email (contact details under [Section 10.0](#)).

The use of high dose norethisterone^{®46} is *not* recommended as a long-term measure for menstrual suppression as this is metabolised to ethinylestradiol and will result in higher estrogen levels than would result from standard combined hormonal contraception.

Options for menstrual suppression include:

7.1 Continuous combined hormonal contraception

This can be effective at suppressing menstrual bleeding but there is still a possibility of breakthrough bleeding requiring an occasional withdrawal bleed. Low estrogen options can be more successful for this indication. As estrogens will cause an increase in SHBG and fall in free testosterone, this is not recommended for patients on testosterone therapy.

Patients may find some side effects unacceptable, particularly breast tenderness and fullness. This can be particularly problematic for patients who bind their chest. Combined hormonal contraception should not be used in those who have medical conditions that would otherwise contraindicate its use⁴⁷.

7.2 Systemic progesterone-based hormonal contraception methods

Breakthrough bleeding can occur with these methods but in patients taking testosterone as well, this is less likely to occur.

7.2.1 Oral medroxyprogesterone acetate (MPA) - Provera^{®48}.

With specialist guidance, a dose of 10 mg twice or three times daily is often effective in suppressing menstrual bleeding even in patients who are not taking testosterone therapy. High dose oral MPA will cause a fall in endogenous estradiol and can lead to bone mineral density loss with long term use in patients who do not use testosterone therapy. Patients should have adequate calcium and Vitamin D intake (with supplementation if necessary). Oral MPA is *not* licensed as a method of contraception so if this is needed additional methods should be used.

7.2.2 Injectable Medroxyprogesterone acetate (MPA) - Depo Provera^{®49} or Sayana Press^{®50}

This treatment also provides effective contraception if used correctly. If menstruation is not fully suppressed, the dose interval of this treatment can be shortened to 8–10 weeks to achieve higher drug levels (off-label recommendation).

7.3 Intrauterine systems

Amenorrhea commonly occurs with the Levonorgestrel Intrauterine System (LNG-IUS), but some people may still experience breakthrough bleeding. It can be a good option for patients who do not wish to have systemic hormone therapy. However, many patients consider the insertion and removal procedure too invasive.

7.4 Gonadotrophin-releasing hormone agonist

Recommendation of a GnRH agonist for menstrual suppression would typically be made by a specialist following specialist evaluation. Ideally patients should be established on testosterone therapy, as GnRH agonist monotherapy will inevitably lead to bone density loss. Patients who do not have adequate sex hormone replacement may also develop menopausal type symptoms. GnRH agonists are *not* licensed as a method of contraception so if this is needed additional methods should be used.

8.0 Other hormone therapy agents

Other hormone therapy agents not included in this guidance document may be prescribed following specialist review from the WGT on a case by case basis or as part of a clinical trial. For non-standard therapies used through self-medication or recommended by a private or non-UK specialist, seek advice from the WGT (see [Section 6.0](#) and [Appendix 1](#)).

9.0 Long-term health screening

Patients and their registered GP should be aware that automatic call-up to National Screening Programs is linked to the gender marker on the primary care record.

It is advised that GP surgeries apply an alert to the primary care record at the time a gender marker is changed. This should provide a prompt for surgery staff to organise only appropriate screening invitations.

Long-term health screening should include self-examination for chest lumps (even after bilateral mastectomy and chest reconstruction surgery), breast screening if breasts are present, bowel screening, and cervical screening if the cervix is present. Trans men on long term testosterone therapy and people who underwent a prior male puberty are advised to attend abdominal aortic aneurysm (AAA) screening⁵¹.

For patients using testosterone GAHT, there is a theoretical risk of endometrial hyperplasia through the action of low levels of estradiol (aromatised from testosterone) unopposed by progesterone. While the uterus is present, the current recommendation is for trans-abdominal ultrasound scanning to assess the endometrium. Scanning should start after 2 years of testosterone therapy and thereafter on a biennial basis. To ensure continuity of care and for practical reasons, this should ideally be requested by the patient's GP, referring any suspected abnormalities to the Welsh Gender Team.

Public Health Wales information for transgender service users can be accessed [here](#).

10.0 Welsh Gender Service contact information

Postal Address:
Welsh Gender Service
St David's Hospital (Ysbyty Dewi Sant)
Cowbridge Road East,
Cardiff
CF11 9XB
Telephone: 02921 836612
General enquiries email: cav.wgs_enquiries@wales.nhs.uk
Clinical advice email: cav.wgs@wales.nhs.uk

References

1. World Health Organization. Gender incongruence and transgender health in the ICD 11th Edition. Available at: <https://www.who.int/standards/classifications/frequently-asked-questions/gender-incongruence-and-transgender-health-in-the-icd>. Accessed May 2023.
2. Welsh Directed Enhanced Service. Hormone Treatment for Adult Patients with Gender Dysphoria/Incongruence after Assessment and Optimisation of Treatment by the Welsh Gender Clinic and Local Intermediate Gender Team. Available at: <https://www.gov.wales/directed-enhanced-service-hormone-treatment-adult-patients-gender-dysphoria>. Accessed May 2023.
3. Hembree WC, Cohen-Kettenis PT, Gooren L et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2017;102(11):3869–3903. Available at: <https://doi.org/10.1210/jc.2017-01658>. Accessed May 2023.
4. British Association of Sexual Health & HIV (BASHH), Recommendations for Integrated Sexual Health Services for Trans Including Non-Binary People, 2019. Available at: <https://www.bashh.org/media/4400/bashh-recommendations-for-integrated-sexual-health-services-for-trans-including-non-binary-people-2019pdf.pdf>. Accessed May 2023.
5. Bayer plc. Nebido® 1000mg/4ml, solution for injection. Summary of Product Characteristics. Nov 2022. Available at: <https://www.medicines.org.uk/emc/product/3873>. Accessed May 2023.
6. Leemaqz SY, Kyinn M, K B et al. Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy. *J Clin Lipidol*. 2023;17(1):103-111. Accessed May 2023.
7. Stangl TA, Wiepjes CM, J D et al. Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy? *European Journal of Endocrinology*. 2021;184(4):513-520. Accessed May 2023.
8. Hashemi L, Zhang Q, Getahun D et al. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy. *Journal of Sex Medicine*. 2021;18(9):1662-1675. Accessed May 2023.
9. Besins Healthcare UK Ltd. Testogel® 16.2mg/g gel Summary of Product Characteristics. Oct 2022. Available at: <https://www.medicines.org.uk/emc/product/8919/smpc>. Accessed May 2023.
10. Besins Healthcare UK Ltd. Testogel® 40.5 mg, transdermal gel in sachet. Feb 2022. Available at: <https://www.medicines.org.uk/emc/product/13255/smpc>. Accessed May 2023.
11. Besins Healthcare UK Ltd. Testogel® 50 mg, transdermal gel in sachet. Mar 2021. Available at: <https://www.medicines.org.uk/emc/product/6808/smpc>. Accessed May 2023.
12. The Simple Pharma Company Limited. Testavan® 20 mg/g Transdermal gel. Summary of Product Characteristics. Jul 2022. Available at: <https://www.medicines.org.uk/emc/product/13936>. Accessed May 2023.
13. Good practice in prescribing and managing medicines and devices. Available at: <https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices>. Accessed May 2023.

Endocrine Management of Gender Incongruence in Adults

14. Kyowa Kirin Ltd. Tostran® 2% Gel. Summary of Product Characteristics. Feb 2020. Available at: <https://www.medicines.org.uk/emc/product/332>. Accessed May 2023.
15. Ohlander SJ, Varghese B, and AW P. Erythrocytosis Following Testosterone Therapy. *Sex Med Rev.* 2018;6(1):77-85. Accessed May 2023.
16. Connelly PJ, Freel M, Perry C et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adult. *Hypertension AHA.* 2019;74(6):1266-1274. Available at: <https://doi.org/10.1161/HYPERTENSIONAHA.119.13080>. Accessed May 2023.
17. Cocchetti C, Ristori J, Romani A et al. Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. *J Clin Med.* 2020;9(6):1609. Available at: doi: 10.3390/jcm9061609. Accessed Jun 2023.
18. Emmanuel M, and BR. B. Tanner Stages. *StatPearls.* 2022. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK470280/>. Accessed May 2023.
19. Totaro M, Palazzi S, C C et al. Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study. *Frontiers in Endocrinology.* 2021;12. Available at: <https://doi.org/10.3389/fendo.2021.741866>. Accessed May 2023.
20. Gregson J, Kaptoge S, and Bolton T. Cardiovascular Risk Factors Associated With Venous Thromboembolism. *JAMA.* 2019;4(2):163-173. Available at: doi:10.1001/jamacardio.2018.4537 Accessed May 2023.
21. Goldstajn MS, Mikus M, Ferrari FA et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review. *Arch Gynecol Obstet.* 2023;307(6):1727-1745. Available at: doi: 10.1007/s00404-022-06647-5. Accessed May 2023.
22. NHS England. PSA testing Prostate Cancer. Available at: <https://www.nhs.uk/conditions/prostate-cancer/psa-testing/>. Accessed May 2023.
23. Aranda G, Halperin I, Gomez-Gil E et al. Cardiovascular Risk Associated With Gender Affirming Hormone Therapy in Transgender Population. *Frontiers in Endocrinology.* 2021;12:718200. Available at: doi: 10.3389/fendo.2021.718200. Accessed May 2023.
24. Choi JY, and Kim TJ. Fertility Preservation and Reproductive Potential in Transgender and Gender Fluid Population. *Biomedicines.* 2022;14(9):2279. Available at: doi: 10.3390/biomedicines10092279. Accessed May 2023.
25. Faculty of Sexual and Reproductive Healthcare. Clinical Standards and Guidance 2022. Available at: <https://www.fsrh.org/standards-and-guidance/>. Accessed May 2023.
26. Orion Pharma UK Limited. Sandrena® 1.0 mg gel. Summary of Product Characteristics. Oct 2022. Available at: <https://www.medicines.org.uk/emc/product/1048/smpc>. Accessed May 2023.
27. Besins Healthcare (UK) Ltd. Oestrogel Pump-Pack 750 micrograms/actuation Gel. Summary of Product Characteristics. Apr 2022. Available at: <https://www.medicines.org.uk/emc/product/353/smpc>. Accessed May 2023.
28. Novartis Pharmaceuticals UK Ltd. Estradot® 25 micrograms/24 hours, transdermal patches. Summary of Product Characteristics. . Jun 2022. Available at: <https://www.medicines.org.uk/emc/product/3869/smpc>. Accessed May 2023.

All Wales Medicines Strategy Group

29. Theramex UK Limited. Evorel® 50 Patches. Summary of Product Characteristics. . Feb 2023. Available at: <https://www.medicines.org.uk/emc/product/10927>. Accessed May 2023.
30. Bayer plc. Progynova® 2 mg tablets. Summary of Product Characteristics. Feb 2023. Available at: <https://www.medicines.org.uk/emc/product/1417/smpc>. Accessed May 2023.
31. Mylan. Elleste Solo® 2 mg Tablets. Summary of Product Characteristics. Mar 2022. Available at: <https://www.medicines.org.uk/emc/product/9513/smpc>. Accessed May 2023.
32. Mylan. Zumenon® 2 mg Film-coated Tablets. Summary of Product Characteristics. Mar 2022. Available at: <https://www.medicines.org.uk/emc/product/1174/smpc>. Accessed May 2023.
33. Shufelt CL, and Manson JE. Menopausal Hormone Therapy and Cardiovascular Disease: The Role of Formulation, Dose, and Route of Delivery. *J Clin Endocrinol Metab*. 2021;106(5):1245-1254. Available at: doi: 10.1210/clinem/dgab042. Accessed May 2023.
34. Wiepjes CM, de Jongh RT, CJM dB et al. Bone safety during the first ten years of gender-affirming hormonal treatment in transwomen and transmen. *Journal of Bone and Mineral Research*. 2019;34(3):447-454. Accessed May 2023.
35. Rothman MS, and Iwamoto SJ. Bone Health in the Transgender Population. . *Clin Rev Bone Miner Metab*. 2019;17(2):77-85. Available at: doi: 10.1007/s12018-019-09261-3. . Accessed May 2023.
36. de Blok CJM, Wiepjes CM, Nota NM et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. *BMJ*. 2019;365:1652. Available at: <https://www.bmj.com/content/365/bmj.l1652>. Accessed Jul 2019.
37. Crowley F, Mihalopoulos M, Gaglani S et al. Prostate cancer in transgender women: considerations for screening, diagnosis and management. *British Journal of Cancer*. 2023;128(2):177-189. Accessed May 2023.
38. Wilson LM, Baker KE, Sharma R et al. Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review. . *Int J Transgend Health*. 2020;21(4):391-402. Available at: doi: 10.1080/15532739.2020.1819505. Accessed May 2023.
39. Coleman E, Radix AE, WP B et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. *International Journal of Transgender Health*. 2022;23(1):1-259. Available at: <https://doi.org/10.1080/26895269.2022.2100644>. Accessed May 2023.
40. Takeda UK Ltd. Prostag® 3 DCS. Summary of Product Characteristics. Apr 2023. Available at: <https://www.medicines.org.uk/emc/product/4651/smpc>. Accessed May 2023.
41. Ipsen Ltd. Decapeptyl® SR 11.25mg (triptorelin pamoate). Summary of Product Characteristics. . May 2022. Available at: <https://www.medicines.org.uk/emc/product/780/smpc#gref>. Accessed May 2023.
42. AstraZeneca UK Limited. Zoladex® LA 10.8mg. Summary of Product Characteristics. May 2023. Available at: <https://www.medicines.org.uk/emc/product/1567/smpc>. Accessed May 2023.
43. Cipla EU Ltd. Finasteride® 5 mg film-coated tablets. Summary of Product Characteristics. Sep 2021. Available at: <https://www.medicines.org.uk/emc/product/9958/smpc>. Accessed May 2023.

Endocrine Management of Gender Incongruence in Adults

44. Rivopharm UK Ltd. Dutasteride® 0.5 mg capsules, soft. Summary of Product Characteristics. Feb 2018. Available at: <https://www.medicines.org.uk/emc/product/8988/smpc>. Accessed May 2023.
45. Nambiar K, Pinto-Sander N, Davis J et al. Hormone self-medicating: A concern for transgender sexual health services. *International Journal of STD & AIDS*. 2018;29(7):732-733. Available at: doi:10.1177/0956462418773213. Accessed May 2023.
46. Wockhardt UK Ltd. Norethisterone 5mg Tablets Specific Product Characteristics. Feb 2017. Available at: <https://www.medicines.org.uk/emc/product/1494/smpc#gref>. Accessed May 2023.
47. UK Medical Eligibility Criteria For Contraceptive Use (UKMEC) 2016 - Amended September 2019. Available at: <https://www.fsrh.org/documents/ukmec-2016/>. Accessed Jan 2023.
48. Pfizer Limited. Provera® 10 mg Tablets. Summary of Product Characteristics. . Feb 2020. Available at: <https://www.medicines.org.uk/emc/product/3547/smpc>. Accessed May 2023.
49. Pfizer Limited. Depo-Provera® 150mg/ml Injection Sterile suspension for injection. Jul 2021. Available at: <https://www.medicines.org.uk/emc/product/6721/smpc#gref>. Accessed May 2023.
50. Pfizer Limited. Sayana Press® 104 mg/0.65 ml suspension for injection. Specific Product Characteristics Sep 2020. Available at: <https://www.medicines.org.uk/emc/product/3148/smpc#gref>. Accessed July 2023.
51. Public Health Wales. Screening for life: Transgender information. Available at: <https://phw.nhs.wales/services-and-teams/screening/information-for-people-who-are-transgender-or-non-binary/>. Accessed Jan 2023.
52. Medicines & Healthcare products Regulatory Agency. Falsified healthcare products. Available at: <https://yellowcard.mhra.gov.uk/falsified>. Accessed May 2023.
53. Aspen. Sustanon® 250, 250mg/ml solution for injection. Summary of Product Characteristics. Dec 2022. Available at: <https://www.medicines.org.uk/emc/product/5373>. Accessed May 2023.
54. Alliance Pharmaceuticals. Testosterone Enantate® 250 mg/ ml Solution for Injection Ampoules. Summary of Product Characteristics. . Jan 2023. Available at: <https://www.medicines.org.uk/emc/product/3733/smpc>. Accessed May 2023.

Updates

Date of update	Update details
August 2023 update	
Title	<ul style="list-style-type: none"> Updated from 'Endocrine management of gender dysphoria' to 'Endocrine management of gender incongruence'.
Throughout	<ul style="list-style-type: none"> References updated as required. Based on feedback received, the order of information in each section has been altered to improve ease of use. For example, general aims of treatment are grouped together, followed by the prescribing recommendations that apply to all forms of the relevant therapy. The flowcharts (previously located at the back of the document) are now presented within the relevant sections.
Glossary	<ul style="list-style-type: none"> Expanded to include additional terms.
1.0 Introduction	<ul style="list-style-type: none"> Added clarification that this document only refers to treatment of patients aged 18 years and over. Added signpost to current direct enhanced service details.
2.0 Pathway	<ul style="list-style-type: none"> Updated to reflect current service specification, including amending the referral age from '17.5 years and over' to '17 years and over'.
3.0 Testosterone therapy	<ul style="list-style-type: none"> Blood test requirements updated (baseline tests now include U&E plus bone profiling; titration tests no longer include liver function and lipids unless indicated; annual tests no longer include HbA_{1c}). More information provided on transdermal gel dosages. Information on short-acting intramuscular testosterone injection now separated out into Appendix 2. Recommended application site(s) for transdermal gel have been updated. Calculation examples have been removed. Information regarding national screening programmes and long-term health screening have been moved to Section 9.0.
4.0 Estrogen therapy	<ul style="list-style-type: none"> Added further information regarding venous thromboembolism risk. Transdermal estrogens are now recommended first line, rather than oral therapy. Blood test requirements updated (baseline tests now include U&E plus bone profiling; titration tests no longer include liver function and lipids unless indicated; annual tests no longer include HbA_{1c}). Recommended application site(s) for transdermal gel have been updated. Added Table 2 to aid calculating switching from oral to transdermal estradiol therapy. Information regarding national screening programmes and long-term health screening have been moved to Section 9.0.

Endocrine Management of Gender Incongruence in Adults

Date of update	Update details
5.0 Gonadotrophin-releasing hormone agonist and anti-androgen treatments	<ul style="list-style-type: none"> Table 4 has been updated to reflect current guidelines. Added dutasteride as an alternative preparation to finasteride.
6.0 Self-medication and private care	<ul style="list-style-type: none"> Added in response to the increasing number of GP enquiries about self-medication and the request for endocrine input in relation to recommendations from private specialist providers.
7.0 Menstrual suppression	<ul style="list-style-type: none"> Pre-existing information included and expanded on in standalone section, in response to GP enquiries and in line with current Welsh Gender Team (WGT) pathways regarding offering support with menstrual suppression.
8.0 Other hormone therapy agents	<ul style="list-style-type: none"> Added to ensure this document acknowledges the other compounds used in self-medicated and private care.
9.0 Long-term health screening	<ul style="list-style-type: none"> Pre-existing information included and expanded on in standalone section, in response to GP enquiries. Including breast cancer screening, ascending aortic aneurysm (AAA) screening.
10.0 Contact information	<ul style="list-style-type: none"> Information updated.
Appendix 1 Harm reduction prescribing	<ul style="list-style-type: none"> Added in response to GP enquiries and in line with current WGT pathways regarding offering harm reduction support.
Appendix 2 Short-acting intramuscular testosterone	<ul style="list-style-type: none"> Information moved out of the Section 3.0, to reflect this treatment being less commonly recommended or used.
July 2024 update	
Appendix 1 Harm reduction prescribing	<ul style="list-style-type: none"> Wording on fertility preservation removed to align with the specifications of commissioned services as determined by NHS Wales Joint Commissioning Committee.
October 2024 update	
5.0 Gonadotrophin-releasing hormone agonist and anti-androgen treatments – prescribing recommendations	<ul style="list-style-type: none"> Wording on GnRH added <p>Please note – When prescribing GnRH agonists, the prescriber must endorse the prescription with the reference 'SLS'.</p> <p>SLS added to glossary</p>

Appendix 1. Harm reduction prescribing

Trans, non-binary, and gender diverse people sometimes self-medicate with prescription-only medicines or other compounds obtained without a prescription, often from an unregulated website. They usually do this because they have been unable to have timely access to NHS specialist care. However, some of the physical changes that can result from use of hormone therapy may be permanent, and some people are at risk of serious harm or even death from their misuse. Consequently, it is important that patients who are self-medicating engage in medical care, so that the Welsh Gender Team (WGT), in collaboration with their GP, can consider if substituting a harm-reduction prescription is in their best interests.

'Harm reduction' is a set of practical strategies intended to substitute the patients from self-medication, over to drug therapy of known quality, with appropriate medical monitoring, until the patient who is on an NHS Gender Identity Clinic waiting list receives diagnostic evaluation and definitive advice about long-term treatment.

Around half of internet sites offering medication without prescription sell counterfeit medicines. Counterfeit medicines may:

- Contain a different active ingredient from that indicated in the package labelling;
- Contain a different dose from that indicated in the package labelling;
- Not contain any active ingredient;
- Contain contaminants that constitute a serious toxicity or infection risk.

The extent and risks to patients from self-medication with counterfeit medicines are well-described by international law enforcement agencies⁵². The sale of counterfeit prescription-only drugs medicines is a criminal offence. Their use constitutes a serious risk to health, including risk of permanent disability and death. Doctors should never encourage or condone the use of irregularly sourced prescription-only medication. Doctors and patient with information that could help the MHRA track down people responsible for counterfeit medicines and devices can e-mail their concerns to the Medicines and Healthcare products Regulatory Agency (MHRA) at counterfeit@mhra.gsi.gov.uk or ring their 24-hour hotline on 020 3080 6701.

In the circumstances specified in the relevant [GMC guidance](#), and with specialist guidance, GPs may substitute an NHS prescription for patients already self-medicating with hormone and other endocrine agents obtained without a doctor's prescription. The aim being to reduce potentially serious harm related to self-medicating with prescription only medicines, where there is no monitoring, or guaranteed content and quality of the medication.

Doctors approached by patients seeking a prescription for hormone and other endocrine agents in this context, but who have not received a treatment recommendation from an experienced gender specialist*, should refer to the Welsh Gender Service via Welsh Clinical Communications Gateway (WCCG) for advice.

* The GMC defines 'an experienced gender specialist' as someone who will have evidence of relevant training and at least two years' experience working in specialised practice

Endocrine Management of Gender Incongruence in Adults

The WGT will screen the GP request with a view to offering a one-off appointment with a specialist clinician to the patient, in parallel with placing them on the main waiting list, if not already undertaken. The registered GP might be asked to support the undertaking of baseline blood tests in preparation.

Following consultation, the WGT will provide a comprehensive letter, including an outline of prescribing recommendations on a case-by-case basis with details of further monitoring requirements, as appropriate. NHS-prescribed harm reduction regimens are almost exclusively fixed dose. In harm-reduction prescribing, the purpose of blood tests is to monitor safety parameters and not to inform adjustments in hormone dose.

The WGT will not at this stage undertake a diagnostic assessment or recommendation regarding the appropriateness of long-term hormone therapy in the context of the patient's gender identity-related concerns. The WGT will provide appropriate signposting for support.

Follow-up

The WGT will remain active in providing clinical oversight until such time as the patient reaches the top of the main waiting list for the Welsh Gender Service or equivalent NHS Gender Identity Clinic. The clinical advice email service (cav.wgs@wales.nhs.uk) can also be used for reporting any psychological difficulties encountered by the patient in relation to the new regimen. Patient review by the WGT will be tailored to the specific needs of the individual patient. Changes to the patient's circumstances relevant to this care pathway should be reported by the GP.

Appendix 2. Short-acting intramuscular testosterone

Short-acting injectable preparations are associated with a larger variation in serum testosterone levels over the cycle of administration and are therefore less preferred to the long-acting injectable preparation. Higher rates of polycythaemia are also observed⁵³ so it tends not to be recommended for long term use.

Short-acting injectable testosterone might be recommended as a starting point where gel therapy is not advised, e.g., in severe skin sensitivity, in circumstances where there is a significant risk of skin-to-skin transfer.

The most commonly used product on the market is **Sustanon^{®53}**, which has a licence for use in this context and is the preparation of choice.

Testosterone enantate⁵⁴ is used 'off-label' at an equivalent dose for patients with allergy to nut or soya.

For non-specialist prescribers wanting support and guidance with management of a patient already established on this treatment, contact the WGT. Self-administration of short acting intramuscular, if feasible, reduces the demand on primary care resources.